Literature DB >> 18379371

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

Vienna Ludovini, Stefania Gori, Lorenza Pistola, Maria Agnese Della Fazia, Danilo Piobbico, Giuseppe Servillo, Antonella Flacco, Cristina Scuderi, Lucio Crinò.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18379371     DOI： 10.1097/JTO.0b013e318169e341

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature.

Authors:  Qi Zhu; Mingyun Jiang; Wenfei Li; Shuangli Sun; Jisheng Li; Justin Stebbing; Xiaodong Liang; Ling Peng
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

2.  Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Authors:  Caterina Peraldo-Neia; Giuliana Cavalloni; Elisabetta Fenocchio; Celeste Cagnazzo; Loretta Gammaitoni; Stefano Cereda; Guglielmo Nasti; Maria Antonietta Satolli; Giuseppe Aprile; Michele Reni; Antonio Avallone; Rosella Spadi; Tiziana Venesio; Vittoria Martin; Claudio Doglioni; Milo Frattini; Massimo Aglietta; Francesco Leone
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.